| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99284 |
Emergency department visit for the evaluation and management, high severity |
9,119 |
7,621 |
$1.35M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
9,880 |
8,609 |
$1.26M |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
3,730 |
3,056 |
$254K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
1,886 |
1,495 |
$152K |
| 99221 |
|
343 |
286 |
$142K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
1,395 |
1,179 |
$124K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
1,697 |
1,480 |
$120K |
| 71045 |
Radiologic examination, chest; single view |
1,068 |
837 |
$114K |
| 99239 |
Hospital discharge day management, more than 30 minutes |
317 |
276 |
$108K |
| 99218 |
|
362 |
204 |
$93K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
1,514 |
1,122 |
$89K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
498 |
447 |
$80K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
830 |
621 |
$68K |
| 99217 |
|
235 |
158 |
$59K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
1,807 |
472 |
$52K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
12,346 |
8,444 |
$51K |
| 80053 |
Comprehensive metabolic panel |
9,452 |
6,834 |
$50K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
2,017 |
1,721 |
$41K |
| 36415 |
Collection of venous blood by venipuncture |
15,094 |
10,357 |
$32K |
| 73630 |
|
883 |
475 |
$31K |
| 71046 |
Radiologic examination, chest; 2 views |
146 |
123 |
$22K |
| G0378 |
Hospital observation service, per hour |
280 |
103 |
$13K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
64 |
58 |
$12K |
| 99231 |
Subsequent hospital care, per day, straightforward or low complexity |
21 |
12 |
$11K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
252 |
217 |
$9K |
| 81001 |
|
3,457 |
2,804 |
$8K |
| 84484 |
|
987 |
640 |
$7K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
226 |
210 |
$6K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
279 |
152 |
$6K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
184 |
120 |
$6K |
| 80050 |
General health panel |
37 |
37 |
$5K |
| 83735 |
|
1,471 |
652 |
$5K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
16 |
14 |
$4K |
| 83605 |
|
578 |
435 |
$4K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
572 |
284 |
$3K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
150 |
105 |
$3K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
304 |
253 |
$3K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
92 |
63 |
$3K |
| 84100 |
|
1,087 |
509 |
$3K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
484 |
415 |
$2K |
| 80061 |
Lipid panel |
225 |
191 |
$2K |
| 70450 |
Computed tomography, head or brain; without contrast material |
12 |
12 |
$2K |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
80 |
59 |
$1K |
| 85610 |
|
521 |
353 |
$1K |
| 83690 |
|
274 |
238 |
$1K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
66 |
60 |
$1K |
| 80306 |
|
107 |
96 |
$1K |
| 87040 |
|
220 |
156 |
$1K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
395 |
249 |
$1K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
307 |
90 |
$985.64 |
| 84443 |
Thyroid stimulating hormone (TSH) |
57 |
54 |
$745.09 |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
22 |
12 |
$722.36 |
| 87430 |
|
118 |
99 |
$558.68 |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
45 |
36 |
$543.03 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
95 |
87 |
$470.50 |
| 84145 |
|
32 |
25 |
$389.54 |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
12 |
12 |
$386.66 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
31 |
27 |
$260.21 |
| 99308 |
Subsequent nursing facility care, per day, straightforward |
149 |
73 |
$230.32 |
| 81003 |
|
364 |
304 |
$214.14 |
| 86140 |
|
66 |
48 |
$203.63 |
| 86376 |
|
16 |
15 |
$172.97 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
19 |
17 |
$167.62 |
| 99309 |
Subsequent nursing facility care, per day, low to moderate complexity |
99 |
56 |
$161.79 |
| P9604 |
Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge |
314 |
174 |
$159.69 |
| 85379 |
|
12 |
12 |
$104.54 |
| 87807 |
|
14 |
12 |
$104.43 |
| 87081 |
|
32 |
30 |
$94.21 |
| 82553 |
|
29 |
12 |
$69.90 |
| 80331 |
|
19 |
18 |
$65.24 |
| J3490 |
Unclassified drugs |
153 |
94 |
$27.92 |
| 80366 |
|
18 |
17 |
$17.02 |
| 80373 |
|
18 |
17 |
$17.02 |
| 80344 |
|
18 |
17 |
$17.02 |
| 80355 |
|
18 |
17 |
$17.02 |
| 80377 |
|
18 |
17 |
$17.02 |
| 80338 |
|
18 |
17 |
$17.02 |
| 80372 |
|
18 |
17 |
$17.02 |
| 80337 |
|
18 |
17 |
$17.02 |
| 80370 |
|
18 |
17 |
$17.02 |
| 80334 |
|
18 |
17 |
$17.02 |
| 80357 |
|
18 |
17 |
$17.02 |
| 80341 |
|
18 |
17 |
$17.02 |
| 80368 |
|
18 |
17 |
$17.02 |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
192 |
124 |
$0.00 |
| 80360 |
|
18 |
17 |
$0.00 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
92 |
77 |
$0.00 |
| 80361 |
|
18 |
17 |
$0.00 |
| 82570 |
|
18 |
17 |
$0.00 |
| 80348 |
|
18 |
17 |
$0.00 |
| 80326 |
|
18 |
17 |
$0.00 |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
31 |
26 |
$0.00 |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
109 |
53 |
$0.00 |
| 80354 |
|
18 |
17 |
$0.00 |
| 80365 |
|
18 |
17 |
$0.00 |
| J2272 |
Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg |
15 |
12 |
$0.00 |
| 80364 |
|
18 |
17 |
$0.00 |
| 83992 |
|
18 |
17 |
$0.00 |
| 80346 |
|
18 |
17 |
$0.00 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
127 |
65 |
$0.00 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
360 |
308 |
$0.00 |
| 80359 |
|
18 |
17 |
$0.00 |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
19 |
12 |
$0.00 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
28 |
26 |
$0.00 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
16 |
14 |
$0.00 |
| 80353 |
|
18 |
17 |
$0.00 |
| J2704 |
Injection, propofol, 10 mg |
89 |
62 |
$0.00 |
| 80367 |
|
18 |
17 |
$0.00 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
28 |
15 |
$0.00 |
| 80358 |
|
18 |
17 |
$0.00 |
| 80371 |
|
18 |
17 |
$0.00 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
17 |
12 |
$0.00 |